Background/Aims: Arachidonic acid (AA) and its metabolites are important endogenous lipid messengers. In this study, we test the effect of Leukotriene B 4 (LTB 4 ), a 5-lipoxygenase metabolite of AA, on L-type calcium channels in A7r5 rat aortic vascular smooth muscle cells. Methods: L-type calcium channel currents were recorded by a patch-clamp technique. The mRNA expression of Ca V 1.2 was determined by Real-time RT-PCR. The protein expression of Ca V 1.2 and p38 activity was determined by Western blot analysis. Results: LTB 4 inhibits L-type channel currents in A7r5 cells in a dose-and time-dependent manner. LTB 4 reduced the mRNA/protein expression of Ca V 1.2 channels in A7r5 cells. BLT1 receptor antagonist LY29311 abrogated the inhibitory effect of LTB 4 , while BLT2 receptor antagonist LY255283 had no effect. 5Z-7-oxozeaenol and SB203580, which block TAK1 and p38 kinase respectively, abrogated the LTB 4 inhibitory effect on L-type calcium channels. LTB 4 increased p38 activity in A7r5 cells. Blockage of Src, PI3K, JNK and NF-κB kinase had no effects on LTB 4 inhibition of L-type calcium channel currents in A7r5 cells. Conclusion: We conclude that LTB 4 inhibits L-type calcium channels through BLT1-TAk1-p38 signaling pathway. The LTB 4 inhibitory effect on L-type calcium channels may be involved in its pathological processes such as atherosclerosis.
Introduction
Arachidonic acid (AA) and its metabolites are important endogenous lipid messengers. The effects of AA and its metabolites on low voltage gated T-type calcium channels have been well studied. AA inhibits all T-type (Ca V 3.1, Ca V 3.2 and Ca V 3.3) calcium channels, and T-type calcium channels can be regulated by various metabolites of AA such as epoxyeicosatrienoic determined by peak currents using the following protocol. The cells were held at −50 mV and depolarized in 10-mV steps from −70 to +10 mV at 10-s intervals upon repolarization to −50 mV. For steady-state channel inactivation, the cells were tested at +10 mV from a pre-pulse incremented in 10 mV (−90 mV to +50 mV; 10 s) upon repolarization to −90 mV. The currents were sampled at 10 kHz and filtered at 2 kHz, and corrected online for leak and residual capacitance transients using a P/4 protocol.
Western blot
Cells were lysised with HEPES-NP40 buffer (20 mM HEPES, 150 mM NaCl, 0.5% NP-40, 10% Glycerol, 2 mM EDTA, with 1% Protease Inhibitor Cocktail (Sigma) and 1% Phosphatase Inhibitor Cocktail 2 (Sigma), pH 7.5). The protein samples were resolved using 10% SDS PAGE and transferred to polyvinyldifluoride (PVDF) membranes in a transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, v/v). The PVDF membranes were blocked with 10% nonfat dry milk in TBST for 1 h at room temperature, and incubated with the primary antibody (anti-Ca V 1.2, 1:500 (University of California, Davis); anti-p38 MAPK and antiPhospho-p38 MAPK , 1:1000 (Cell Signaling Technology); anti-GAPDH, 1:5000 (KangChen Bio-Tech)) in TBST with 5% BSA overnight at 4℃. The blot was incubated with a horseradish peroxidaseconjugated secondary antibody and developed using enhanced chemiluminescence (ECL) reagents from Pierce and the ChemiDoc XRS+ imaging system from Bio-Rad.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from cells using RNeasy mini kit purchased from QIAGEN following the manufacturer's instructions. Samples were analyzed in duplicate in five independent runs. A portion (5%) of each first-strand reaction was assayed. Amplification was performed with primers targeted to Ca V 1.2 channels and GAPDH (Ca V 1.2: the forward primer, 5'-TCA AAG GCT ACC TGG ACT GGAT-3' and reverse primer, 5'-CCA TGC CCT CGT CCT CATT-3'; GAPDH: forward primer, 5'-TGC TCC TCC CTG TTC-3' and reverse primer, 5'-AGC CTT GAC TGT GCC-3'). RT-PCR were performed in MyiQ2 (Bio-Rad) in a total reaction mixture volume of 20ul containing 2ul of the reverse transcription PCR product, 0.4uM of each paired primer and SYBR Green PCR master mix (TOYOBO). The PCR conditions were as follows: 94℃, 10min; 40 cycles of 94℃, 30 s; 60℃, 30 s; 72℃, 30 s; 72℃, 8 min. Cycle threshold (Ct) values and concentrations of samples were calculated by Bio-RAD iCycler software.
Data analysis
The data analysis was performed with Clampfit 10.3 (Axon Instruments) and Origin 8.0 software (OriginLab). The statistical analysis consisted of unpaired or paired Student's t tests. Data are given as the means ± S.E.M, and n indicates the number of tested cells or independent test. P < 0.05 was considered to be a statistically significant difference between groups. Multiple comparisons were analyzed using a one-way analysis of variance (ANOVA) followed by the post hoc Tukey test.
Results

LTB 4 inhibits L-type calcium channel currents in a dose-and time-dependent manner in A7r5 cells
Predominant calcium channel currents in A7r5 cells are conducted by L-type calcium channels [41] . L-type calcium channel currents (Ba 2+ as the charge carrier) in A7r5 cells were elicited by a 100-ms depolarizing pulse to +10 mV from a holding potential of -50 mV (which inactivated T channel currents) at 10 s intervals. In order to avoid any contribution of T channel currents, the 1 µM nifedipine (L-type calcium channel specific blocker) was used to confirm the L-type Ba 2+ currents (Fig. 1A) . Nifedipine-sensitive Ba 2+ currents were used to calculate the LTB 4 effect on L-type calcium channels. 100 nM LTB 4 inhibited L-type calcium currents in a time-dependent manner (percent inhibition: 1 h: 2.7 ± 5.6%, n = 30; 5 h: 7.5 ± 4.0%, n = 62; 12 h: 31.8 ± 3.9%, n = 70; 24h: 12.5 ± 2.6%, n = 72; P < 0.05 by ANOVA, Fig. 1A ). The inhibitory effect reached a maximum at about 12 h, so we used 12 h treatment for all of the following experiments. The current-voltage (I-V) relationship was elicited by a step protocol (holding at −50 mV, depolarizing in 10-mV steps from −70 to +50 mV at 10-s We tested whether LTB 4 inhibited L-type calcium channels through altering the steadystate activation and inactivation of L-type calcium channel currents. As shown in Fig. 2 , 100 nm LTB 4 did not change either the steady-state activation ( Fig. 2A) or inactivation ( Fig.  2B ) kinetics of L channel currents. We then studied whether LTB 4 inhibited L-type channel currents by changing gene expression. A7r5 cells predominately express Ca V 1.2 L-type calcium channels [28] , therefore we tested Ca V 1.2 channel expression. Real-time RT-PCR results showed that LTB 4 decreased mRNA expression of Ca V 1.2 channels in time-dependent manner (Fig. 2C ).Western blot results showed that 12 h treatment with 100 nM LTB 4 reduced Ca V 1.2 channel protein expression significantly (Fig. 2C ).
LTB 4 reduces Ca V 1.2 channel currents through the BLT1 receptor
We then investigated how LTB 4 inhibits L-type calcium channel currents. Both BLT1 and BLT2 receptors are expressed in A7r5 cells (data not shown). As shown in Fig. 3 , the BLT1 receptor antagonist LY293111 (5 µM) abrogated the LTB 4 inhibition of L-type calcium channel currents (Fig. 3A) , but the BLT2 receptor antagonist LY255283 (5 µM) had no effect (Fig. 3B ). LY293111 and LY255283 per se had no effect on L-type calcium channel currents. These data suggested that LTB 4 inhibited L-type calcium channel currents through BLT1 receptors. 4 (1~100 nM) on L-type calcium channels (n = 46~80, *P < 0.05 compared to control using a one-way ANOVA followed by Tukey's test).
LTB 4 decreases Ca V 1.2 channel currents through TAk1 / p38 signaling pathway Through BLT1 receptors, LTB 4 activated several kinase cascades including TAK1, PI3K and Src [42] . As shown in Fig. 4 , the TAK1 inhibitor (5Z)-7-Oxozeaenol (1 µM) abrogated the LTB 4 inhibition of L-type channel currents (Fig. 4A) , while the PI3K inhibitor LY294002 (10 µM) and the Src inhibitor PP2 (10 µM) showed little or no effects (Fig. 4B and C) . (5Z)-7-Oxozeaenol, LY294002 and PP2 per se had no significant effect on L-type calcium channel currents.
TAk1 could regulate gene expression through activating p38, JNK or NF-κB signaling pathway. JNK inhibitor Sp600125, NF-κB pathway inhibitor U0126 and p38 inhibitor SB203580 were used to investigate downstream signaling of TAK1. As shown in Fig. 5, 10 µM SB203580 abrogated the LTB 4 inhibition of Ca V 1.2 channel currents in A7r5 cells (Fig.  5A) . Both Sp600125 (20 µM) and U0126 (10 µM) did not alter the LTB 4 inhibition of Ca V 1.2 channels (Fig. 5B and C) . Sp600125, U0126 and SB203580 per se had no significant effect on L channel currents. These data suggested that LTB 4 inhibited L-type calcium channels through TAK1-p38 signaling pathway in A7r5 cells. 
channels in
A7r5 cells at various time points (1~12 hour, left, *P < 0.05 compared to control using a one-way ANO-VA test); 12 hour treatment with 100 nM LTB 4 significantly reduced protein expression of Ca V 1.2 channels (right); A representative image (Upper) and the statistical analysis of Western blot from 5 independent experiments (*P < 0.05 compared to control, t test , lower). Finally, we test whether LTB 4 activated p38 kinase in A7r5 cells. As shown in Fig. 6 , LTB 4 increased phosphorylation of p38 kinase in a time-dependent manner, and the stimulatory effect reached a maximum at about 15 min (Fig. 6A) . Co-incubation of A7r5 cells with p38 inhibitor SB203580 abrogated the LTB 4 induced decrease of Ca V 1.2 protein expression (Fig.  6B) .
Discussion
In present study, we report that LTB 4 inhibited L-type calcium channels in A7r5 cells via BLT1-TAK1-p38 signaling pathway. The high-affinity LTB 4 receptor BLT1 is predominantly expressed in leukocytes [8] . Previous study shows that A7r5 cells also express BLT1 receptors [38] . We found both mRNA expression of BLT1 and BLT2 receptors in A7r5 cells (data not shown), while only BLT1 inhibitor LY293111 abrogated the LTB 4 inhibition of L-type calcium channel currents.
AA and its metabolites have been shown to directly inhibit T-type calcium channels [1] . AA has also been shown to inhibit L-type calcium channels in a direct way [3] . However, the inhibitory effect of LTB 4 on L-type channel currents was not observed during the course of 10 min perfusion with 100 nM LTB 4 (data not shown), which suggested that LTB 4 inhibited L-type calcium channels in an indirect way. Intracellular calcium plays a key role in physiological function and phenotypic modulation of vascular smooth muscle cells (VSMC) [32, 43] . The changes of intracellular Ca 2+ concentration in VSMC are regulated either by extracellular Ca 2+ entry, or Ca 2+ release from intracellular stores, primarily the sarcoplasmic reticulum. Ca 2+ entry in vascular smooth muscle is mainly regulated by Ca V 1.2 L-type Ca 2+ channels [44] .The Ca 2+ release from the sarcoplasmic reticulum is mediated by ryanodine receptors and inositol triphosphate receptors [45] . A previous study reported that LTB 4 activates ryanodine receptor of cerebellum while has no effect on inositol triphosphate receptor [46] . Ryanodine receptor-mediated Ca 2+ release causes membrane hyperpolarization by activating large-conductance Ca
2+
-activated potassium channels, and leading to inactivation of L-type calcium channels in VSMC [47] . Therefore, LTB 4 may suppress the L-type calcium channel activity in VSMC through multiple ways. By inhibition of L-type calcium channels, LTB 4 may inhibit the expression of contractile phenotype marker genes, and leading to VSMC growth and proliferation [32] .
The vascular smooth muscle cells have two distinct phenotypes: the differentiated contractile phenotype and the dedifferentiated synthetic/proliferative phenotype. L-type calcium channel expression is closely associated with smooth muscle cells phenotype [32] , and considered as a differentiation marker for VSMC. The expression of L-type calcium channels is down-regulated when VSMC phenotype converted from the differentiated into the dedifferentiated state [48] . Knock-down of Ca V 1.2 channels with siRNA in VSMC results in loss of contractile phenotype and vascular remodeling in vivo [49] . Compelling evidence indicates that phenotypic switching of the VSMC plays an important role in various diseases including atherosclerosis, cancer, asthma and hypertension [50] [51] [52] [53] . Among these, atherosclerosis is the most well-known example in which VSMC switching from the differentiated contractile phenotype to the dedifferentiated synthetic phenotype is believed to play a key role [50, 54, 55] . Our data showed that LTB 4 reduced Ca V 1.2 channel expression in A7r5 VSMC, which may partially explain the pathological processes induced by LTB 4 such as atherosclerosis [24, 56] .
Through BLT1 receptor, LTB 4 could activate several kinase cascades including TAK1, PI3K and Src, while our data show that only TAK1 inhibitor abrogated the LTB 4 inhibitory effect on L-type calcium channel currents. Downstream of TAK1, LTB 4 alters gene expression mainly through NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways [42] . Our data shows that the LTB 4 inhibited the expression of Ca V 1.2 channels by activation of p38 MAPK. Our results are in agreement with previous studies [57, 58] . Ihara . reported that PD98059, an inhibitor of MAPK kinase, increases L-type channel expression in primary cultured rat aorta smooth muscle cells [57] . Ouyang et al. reported that blockage of p38 enhances up-regulation of Ca V 1.2 channel expression induced by fluvastatin in vascular smooth muscle cells [58] . Taken together, our results and the two previous findings from other groups indicated that p38 plays an important role in regulating Ca V 1.2 channel expression of VSMC.
In conclusion, our results provide the first evidence that LTB 4 reduces L-type calcium channel currents in A7r5 cells, and the inhibitory effect is mediated via BLT1-TAK1-p38 signaling pathway. The LTB 4 inhibitory effect on L-type calcium channels may be involved in its pathological processes such as atherosclerosis. 
